

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/18	A1	(11) International Publication Number: WO 98/35695 (43) International Publication Date: 20 August 1998 (20.08.98)
(21) International Application Number: PCT/GB98/00316 (22) International Filing Date: 13 February 1998 (13.02.98) (30) Priority Data: 9702943.3 13 February 1997 (13.02.97) GB (71) Applicant (for all designated States except US): THE VICTORIA UNIVERSITY OF MANCHESTER [GB/GB]; Oxford Road, Manchester M13 9PL (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): FERGUSON, Mark, William, James [GB/GB]; 13 Peel Moat Road, Heaton Moor, Stockport SK4 4PL (GB). (74) Agent: ATKINSON, Peter, Birch; Marks & Clerk, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: WOUND HEALING (57) Abstract The present application relates to the use of Latency Associated Peptide, or a functional analogue thereof, for the treatment of wounds such that the rate of wound healing is increased. Preferred agents for use in such treatments include Latency Associated Peptide isolated from cells expressing the same and peptide functional analogues of Latency Associated Peptide.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WOUND HEALING

The present invention relates to the healing of wounds.

Wound healing in adult tissues is a complicated reparative process. In skin for example the healing process involves the recruitment of a variety of specialised cells to the site of the wound, extracellular matrix and basement membrane deposition, angiogenesis, selective protease activity and re-epithelialisation.

There is a need to provide medicaments that promote the healing of wounds. For example, it is often desirable to increase the rate of healing in the case of acute wounds (such as penetrative injuries, burns, nerve damage or even wounds resulting from elective surgery), chronic wounds (such as diabetic, venous and decubitus ulceration) or for generally healing compromised individuals (for example the elderly). In these examples, the wounds can severely influence quality of life or even result in death and therefore the rate of healing often needs to be increased as much as is clinically possible.

The term "wound" as used herein is exemplified but not limited to injuries to the skin. Other types of wound can involve damage, injury or trauma to an internal tissue or organ such as the lung, kidney, heart, gut, tendons or liver.

There have been several recent developments in the wound healing field. Some of these developments revolve around the recent understanding that growth factors are intimately involved in the repair of wounded tissue. In particular, members of the Transforming growth Factor β (TGF- β) superfamily have been found to play an important role in wound healing. At least 25 molecules are known to be members of the TGF- β superfamily. These include a number of cytokines such as TGF- β s 1 to 5, the DVR group (e.g. dpp and Vg1), Bone Morphogenetic Proteins, Nodal, Activin and Inhibin.

TGF- β (and other members of the superfamily) are secreted from cells as a pro-protein which is known as latent TGF- β . The pro-protein consists of an N terminal Latency Associated peptide (LAP) and the TGF- β and is referred to as the Small Latent Complex. Additionally the Small Latent Complex can bind to another peptide (derived from a different gene) of variable size called Latent TGF- β Binding Protein (LTBP) in which case the entire complex is known as the Large Latent TGF- β Complex.

Upon secretion of the pro-protein into the extracellular environment, proteolytic cleavage of LAP (and LTBP) from TGF- β can occur. However, TGF- β may remain non-covalently associated with LAP. TGF- β is activated when it is caused to be dissociated from the LAP. This dissociation may be coordinated at a mannose-6-phosphate / Insulin Like Growth Factor II receptor (M6P-R) and involve proteases such as plasmin, the substrates being associated at the cell surface by tissue transglutaminase. Free radicals and reactive oxygen species can also activate TGF- β by causing dissociation from the LAP.

TGF- β (particularly TGF- β 1 and TGF- β 2) promotes wound healing but is also associated with increased scar formation and fibrosis. In fact, clinical interest in the modulation of TGF- β has been associated with inhibiting its activity in order to reduce scar formation (although this may compromise the rate of wound healing). For instance, WO 92/17206 discloses compositions which inhibit the activity of TGF- β 1 and TGF- β 2 and are particularly beneficial for reducing scar formation.

Another development in the field involves the use of mannose-6-phosphate for use in treating fibrotic disorders associated with elevated levels of TGF- β (GB 2,265,310). Mannose-6-phosphate is believed competitively to interfere with the liberation of TGF- β from LAP at the M6P-R thereby inhibiting TGF- β activation and preventing fibrosis or scarring.

WO 91/08291 and WO 94/09812 relate to the role of LAP in modulating TGF- β activity and disclose methods of producing LAP and large latent TGF- β respectively. These documents also provide uses of LAP for antagonising or neutralising TGF- β activity by binding to TGF- β and reverting it back to a latent state. It is claimed that a consequence of this antagonism is to reduce scarring following wounding.

According to a first aspect of the present invention there is provided the use of Latency Associated Peptide, or a functional analogue thereof, for the manufacture of a medicament for increasing the rate of wound healing.

According to a second aspect of the present invention, there is provided a method of increasing the rate of wound healing comprising applying to the site of the wound a therapeutically effective amount of Latency Associated Peptide or functional analogue thereof.

The Latency Associated Peptide (LAP) used according to the invention is the N terminal region of the pro-proteins of the Transforming Growth factor β (TGF- β) superfamily of molecules, the said region being capable of maintaining at least one of the members of the TGF- β superfamily in a latent state. It is preferred that the LAP is capable of maintaining a TGF- β in a latent state and most preferred that the LAP will maintain TGF- β 1 and / or TGF- β 2 in a latent state

In accordance with the invention, the inventors have established that LAP may be used to increase the rate at which a wound will heal. For example, in skin, we have found that LAP, or a functional analogue thereof, increases the rate of dermal healing (i.e. an open wound closes quicker when LAP is applied to the wound). This increase in the rate of healing can be further characterised by any of: an increase in the recruitment of a variety of specialised cells to the site of the wound (fibroblasts,

leukocytes etc), an increase in extracellular matrix and basement membrane deposition, increased angiogenesis, increased selective protease activity and quicker re-epithelialisation.

This is a surprising development in the light of conventionally accepted interactions of TGF- β and LAP which are discussed above. According to the teaching of the prior art, LAP would be expected to antagonise or neutralise the effects of TGF- β and thereby reduce scarring and/or fibrosis. Conventionally such an effect would also be expected to result in a reduction in the rate of wound healing (e.g. slower closing of a incisional wound of the skin).

The invention has been based on the inventors' studies which have shown that LAP, contrary to expectations, increases the rate of wound healing. These findings led to the realisation that LAP actually promotes the wound healing effects of TGF- β (and related molecules) and, at least with respect to wound healing, does not neutralise or antagonise TGF- β as suggested by WO 91/08291.

Although the inventors do not wish to be constrained by any hypothesis, they believe it is possible that the mechanism by which LAP is effective in increasing the rate of wound healing is by binding to TGF- β and protecting it from proteolytic degradation. This results in the sequestration of the active TGF- β (particularly TGF- β 1 and TGF- β 2) which is normally present during wound healing. This sequestered TGF- β may then act as a reserve which may be released into the wound and will effectively increase the half life of TGF- β over which time it promotes healing.

We have found that administration of LAP offers advantages over the use of exogenous TGF- β for increasing the rate of wound healing. Administration of exogenous doses of TGF- β can lead to inappropriately high localised concentrations of TGF- β which, as TGF- β increases the rate of wound healing and induces scarring or fibrosis, can cause unacceptable scarring or fibrosis. Administration of LAP, or a

functional analogue thereof, has no such adverse effect and only modulates the activity of endogenously present TGF- β . Thus LAP, or a functional analogue thereof, is particularly useful for increasing the rate of wound healing without causing inappropriate scarring or fibrosis.

We have established that LAP, and functional analogues thereof, increases the rate of wound healing of a variety of wounds including acute wounds (such as penetrative injuries, burns, nerve damage or even wounds resulting from elective surgery). It is however preferred that LAP is used for the treatment of chronic wounds. Examples of such chronic wounds are diabetic, venous or decubitus ulceration. A preferred use of LAP is also for generally healing compromised individuals (for example the elderly).

It will be appreciated that certain amino acids of endogenously expressed LAP may be readily modified, substituted or deleted without destroying the functional characteristics of the LAP peptide. Therefore functional analogues of LAP may be conveniently used according to the invention. These analogues are generally those which when bound to a member of the TGF- β superfamily cause said member to revert to a latent state and protect the TGF- β from proteolytic degradation and/ or clearance. Examples of such analogues are genetically modified mutations of LAP which retain the TGF- β binding characteristics of endogenous LAP or chemical modifications of endogenous LAP. Other analogues are chemically synthesised compounds with similar binding affinities for members of the TGF- β superfamily as that of LAP. Functional analogues referred to herein also include fragments of LAP which retain the binding affinity of LAP for members of the TGF- β superfamily.

It will also be appreciated that LAPs derived from different members of the TGF- β superfamily may exhibit variations in their amino acid sequences but still retain the functional characteristic that they may bind to a member of the TGF- β

superfamily and cause said member to revert to a latent state. Each of these LAPs may be used according to the invention.

LAP or protein analogues thereof for use according to the invention may be obtained from tissues or cells grown in culture which express at least one member of the TGF- β superfamily. Preferably the tissues or cells express a TGF- β and most preferably TGF- β 1 or TGF- β 2.

Alternatively LAP or protein analogues thereof may be obtained from cells that have been genetically engineered to express LAP or protein analogues thereof (for instance as disclosed in WO 91/08291) or from a transgenic animal genetically engineered to express LAP or protein analogues thereof. Ideally the transgenic animal secretes LAP or protein analogues thereof. For instance transgenic mammals may secrete LAP, or protein analogues thereof, in their milk.

It is preferred that recombinant LAP from genetically engineered cells is used according to the invention because sufficient quantities of LAP for therapeutic use may be conveniently generated from such a source. This recombinant LAP may have the same amino acid sequence as endogenously occurring LAP. Alternatively, LAP may be modified as required. For example, Cys33 of LAP may be mutated to a serine residue to prevent the formation of undesirable disulphide bridges.

The medicament of the invention may take a number of different forms depending, in particular on the manner in which the medicament is to be used. Thus, for example, the medicament may be in the form of a liquid, ointment, cream, gel, hydrogel, powder, aerosol or an implantable device (e.g. by conjugation to a biopolymer (collagen or proteoglycan) sponge).

It is preferred that the medicaments are for topical application. The medicament may be most suitably used for topical application to the skin or wound area.

It will be appreciated that the vehicle of the medicament should be one which is well tolerated by the patient and allows release of LAP, or a functional analogue thereof, to the wound. The vehicle will ideally be sterile and may be combined with excipients and / or stabilizers as well as LAP, and functional analogues thereof, to form the medicament. Such a vehicle is preferably biodegradable, bioresolvable, bioresorbable and/or non-inflammatory.

The medicament may be used in a number of ways. Thus, for example, it may be applied in, and/or around a wound of a patient to provide the desired promotion of wound healing. If the composition is to be applied to an "existing" wound, then the pharmaceutically acceptable vehicle will be "mild" enough such that it does not cause an inflammatory response or is toxic to the tissue.

The medicament may be provided on a sterile dressing or patch which may be used to cover or even pack a wound to be treated.

The medicament may be provided as an implantable device from which it may be released better. For instance, it may be released by biological dissolution or degradation of the device. Alternatively an external stimulus, such as ultrasound, may cause release of the Latency Associated Peptide or functional analogue thereof from the implant. The medicament may also be incorporated into an implant device to remain active *in situ* (e.g. by conjugation of the device using a suitable linker).

The medicament may be used in a range of internal wound healing applications. Thus for example, the composition may be formulated for inhalation for

use in wound healing of the lungs or may be applied to internal organs for the promotion of healing of internal injuries (e.g. of the liver or bowel).

It is also possible to use medicaments in accordance with the invention in a prophylactic manner. For instance, the medicament may be applied prior to surgery so as to provide for regulation of healing of the subsequently formed surgical wound. In this case the vehicle of the composition will need to be one capable of going across the keratinous layer of the skin. Examples of suitable vehicles for this purpose include dimethyl sulphoxide and acetic acid. Alternatively the medicament may be administered prophylactically before wounding by intradermal injection. Administration by injection is particularly suited when the Latency Associated Peptide or functional analogue thereof is LAP itself or some other protein analogue.

It will be appreciated that the amount of LAP, or functional analogue thereof, required to increase the rate of wound healing depends on a number of factors such as its biological activity and bioavailability, which in turn depends on the mode of administration and the physicochemical properties of the LAP, or functional analogue thereof. Other factors include:

- A) The specific condition to be treated.
- B) The severity of the condition.
- C) The age of the subject.
- D) The site of delivery of LAP.
- E) The half-life of the compound in the subject being treated.

The frequency of administration will also be influenced by the above mentioned factors and particularly the half-life of the compound within the subject being treated.

Generally, a subject being treated will derive benefit from the application of LAP, or functional analogue thereof, if it is administered to a wound within 3 days of

wounding, preferably within 48 hours of wounding, more preferably within 24 hours of wounding and even more preferably within 12 hours of wounding. Ideally when the compositions are used to treat existing wounds the LAP, or functional analogue thereof should be administered as soon as the wound has occurred. Therapy with the LAP, or functional analogue thereof, should continue until the wound has healed to a clinicians satisfaction.

For acute wounds and wounds of subjects who are healing competent (e.g. the young) application of LAP, or functional analogue thereof, will ideally be at the time of wounding, preferably within 12 hours of wounding and no longer than a few days post-wounding. For chronic wounds or wounds in the healing compromised (e.g. the elderly) administration should be as soon as possible but as these wounds are long standing patients may benefit from the use of LAP days (or even weeks) after the wound first formed.

When used as a prophylactic (e.g. before surgery) the LAP, or functional analogue thereof, should be administered as soon as it is recognised that a wound may occur and particularly when there is a risk of a poor rate of wound healing (as may be the case in elderly subjects). For instance, a cream or ointment containing LAP, or functional analogue thereof may be applied to a site on the skin of a subject where elective surgery is to be performed and an increased rate of wound healing is subsequently desired. In this case, the composition may be applied during the preoperative preparation of the subject or it may even be desirable to apply the composition in the hours or days preceding the surgery (depending upon the health status and age of subject as well as the size of the wound to be formed).

Frequency of administration will depend upon the biological half-life of the compound used. Typically a cream or ointment containing LAP, or functional analogue thereof should be administered to a target tissue such that the concentration

of the compound at the wound site is maintained at a level suitable for having a therapeutic effect. This may require administration daily or even several times daily.

Known procedures, such as those conventionally employed by the pharmaceutical industry (e.g. *in vivo* experimentation, clinical trials etc), may be used to establish specific formulations of compositions and precise therapeutic regimes (such as daily doses of the compounds and the frequency of administration).

Generally, for use in accordance with the invention a medicament containing an amount of 1ng to 10mg of LAP, more preferably 1 μ g to 1mg of LAP, may be applied per centimetre of linear wound. Purely by way of example, a medicament containing 5 μ g LAP is suitable for application to a 1 cm linear incisional wound. Higher doses are required to stimulate the healing of chronic wounds compared to acute wounds.

Efficacy of medicaments, and particularly those formulated for application to chronic wounds, have enhanced efficacy when combined with a protease inhibitor (e.g. galadrin) Protease inhibitors prevent or retard the degradation of the applied LAP, or functional analogue thereof, by proteases which may be found in high levels in wounds, particularly chronic wounds. The protease inhibitor is preferably a broad spectrum protease inhibitor.

It will be appreciated that LAP may be used in combination with other wound healing agents or followed by another agent (e.g. for prevention of scarring).

A preferred means of using a protein or peptide of LAP is to deliver the compound to the wound by means of gene therapy.. Therefore according to a third aspect of the present invention there is provided a delivery system for use in a gene therapy technique, said delivery system comprising a DNA molecule encoding for a LAP, or functional peptide analogue thereof, which modulates wound healing, said

DNA molecule being capable of being transcribed to lead to the expression of said LAP, or functional peptide analogue thereof.

According to a fourth aspect of the present invention there is provided the use of a delivery system as defined in the preceding paragraph for use in the manufacture of a medicament for increasing the rate of wound healing.

According to a fifth aspect of the present invention there is provided a method of increasing the rate of wound healing comprising administering to a patient in need of treatment a therapeutically effective amount of a delivery system as defined for the third aspect of the invention.

The delivery systems are highly suitable for achieving sustained levels of a LAP, or functional peptide analogue thereof, at a wound site over a longer period of time than is possible for most conventional delivery systems. LAP, or functional peptide analogue thereof, may be continuously expressed from cells at the wound site that have been transformed with the DNA molecule of the third aspect of the invention. Therefore, even if the LAP, or functional peptide analogue thereof, has a very short half-life as an agent *in vivo*, therapeutically effective amounts may be continuously expressed from the treated tissue.

Furthermore, the delivery system of the invention may be used to provide the DNA molecule (and thereby the LAP, or functional peptide analogue thereof which is an active therapeutic agent) without the need to use conventional pharmaceutical vehicles such as those required in ointments or creams that are contacted with the wound. This is particularly beneficial as it can often be difficult to provide a satisfactory vehicle for a compound for use in wound healing (which are required to be non-inflammatory, biocompatible, bioresorbable and must not degrade or inactivate the active agent (in storage or in use)).

The delivery system is such that the DNA molecule is capable of being expressed (when the delivery system is administered to a patient) to produce LAP, or functional peptide analogue thereof, which has activity for wound healing.

The DNA molecule may be contained within a suitable vector to form a recombinant vector. The vector may for example be a plasmid, cosmid or phage. Such recombinant vectors are highly useful in the delivery systems of the invention for transforming cells with the DNA molecule.

Recombinant vectors may also include other functional elements. For instance, recombinant vectors can be designed such that the vector will autonomously replicate in the nucleus of the cell. In this case, elements which induce DNA replication may be required in the recombinant vector. Alternatively the recombinant vector may be designed such that the vector and recombinant DNA molecule integrates into the genome of a cell. In this case DNA sequences which favour targeted integration (e.g. by homologous recombination) are desirable. Recombinant vectors may also have DNA coding for genes that may be used as selectable markers in the cloning process.

The recombinant vector may also further comprise a promoter or regulator to control expression of the gene as required.

The DNA molecule may (but not necessarily) be one which becomes incorporated in the DNA of cells of the subject being treated. Undifferentiated cells may be stably transformed leading to the production of genetically modified daughter cells (in which case regulation of expression in the subject may be required e.g. with specific transcription factors or gene activators). Alternatively, the delivery system may be designed to favour unstable or transient transformation of differentiated cells in the subject being treated. When this is the case, regulation of expression may be less important because expression of the DNA molecule will stop when the transformed cells

die or stop expressing the protein (ideally when the wound, fibrosis or scarring has been treated or prevented).

The delivery system may provide the DNA molecule to the subject without it being incorporated in a vector. For instance, the DNA molecule may be incorporated within a liposome or virus particle. Alternatively the "naked" DNA molecule may be inserted into a subject's cells by a suitable means e.g. direct endocytotic uptake.

The DNA molecule may be transferred to the cells of a subject to be treated by transfection, infection, microinjection, cell fusion, protoplast fusion or ballistic bombardment. For example, transfer may be by ballistic transfection with coated gold particles, liposomes containing the DNA molecule, viral vectors (e.g. adenovirus) and means of providing direct DNA uptake (e.g. endocytosis) by application of plasmid DNA directly to the wounded area topically or by injection.

Whilst the above considerations mainly apply to wounds of man it will be appreciated that wound healing, can also be problematic in other animals (especially veterinary and domestic animals such as cattle, horses, dogs, cats etc). For instance, abdominal wounds or adhesions are a major reason for having to put down horses. The medicaments and delivery systems discussed above are also suitable for use in the healing of such animals.

The present invention will now be further described with reference to the following non-limiting example.

EXAMPLE

The effect of LAP on wound healing was assessed using a rat model.

1. METHODS

Full details of the experimental procedures described below, which are all conventional are given in Shah *et al.* (1994) J. Cell Sci. 107 p1137-1157. Briefly, the following experimental steps were taken:

Adult male Sprague-Dawley rats weighing 225-250g were anaesthetised by halothane, nitrous oxide and oxygen inhalation. Four full-thickness, linear incisions, 1cm in length, down to and including the panniculus carnosus were made on the dorsal skin of the animal. The incisions were placed equidistant from the midline and adjacent to the four limbs.

One of the wounds was left unmanipulated as a control. Two wounds were injected intradermally with 100 μ l (50 μ l down each wound margin) of phosphate buffered saline containing recombinant LAP (0.04 μ g, 0.4 μ g or 4.0 μ g). The fourth wound was injected intradermally with an equivalent volume (100 μ l - 50 μ l down each wound margin) of the vehicle in which LAP was dissolved (phosphate buffered saline) as a sham control. Animals were injected just before wounding, 24 and 48 hours later.

Animals were killed and the wounds were harvested at the following times post wounding: 2 hours, 3 hours, 12 hours, 24 hours, 4 days, 7 days, 40 days and 80 days. At each time point there were at least 4 rats per treatment (i.e. n = at least 4 for each dose of LAP used).

Wounds were processed for routine histology by fixation, wax embedding, sectioning and staining. Alternatively wounds were processed for immunocytochemistry by embedding in OCT compound, freezing in liquid nitrogen, cryosectioning and immunostaining with a variety of antibodies to detect TGF- β 1, TGF- β 2, TGF- β 3, TGF- β receptor type II, fibronectin, collagen, monocytes and macrophages, etc.

Histological and immunocytochemical preparations were studied carefully for the effect of LAP on wound healing (especially any anti-scarring effect as would be expected from the prior art). Particular attention was paid to the organisation and orientation of collagen and extracellular matrix molecules deposited at the wound site.

2. RESULTS

None of the treatments resulted in an anti-scarring effect. At 80 days and 40 days post wounding the LAP treated wounds were no different from controls in terms of scar quality or quantity.

Surprisingly, however, at the earlier time points post wounding the LAP treated wounds showed a number of differences from control or sham control wounds. In all cases, these responses were dose dependant, i.e. the least effect was seen at the dose of 0.04 μ g LAP and the highest effect at 4 μ g of LAP.

There was a dose dependant increase in inflammatory cells (monocytes and macrophages) in the LAP treated wounds. Likewise there was a dose dependent increase in fibronectin staining within the early wound site (i.e. up to 14 days post wounding) and an increase in collagen deposition. The LAP treated wounds also showed fibronectin and collagen deposition, as well as inflammatory cells earlier than was seen in the control wounds. Interestingly from 3 hours post wounding until 14 days post wounding the LAP treated wounds showed a dose dependent increase in staining for the TGF β type I receptor and type II receptor. This elevated staining for the TGF β receptor is different from that present in control or sham control wounds. In PBS treated sham control wounds, TGF β receptor I staining increased at 3 hours post wounding, but then decreased within 24 hours post wounding. In unmanipulated wounds there was no early increase in TGF β receptor staining at the wound site. By

contrast the LAP treated wounds showed a dose dependent increase in TGF β receptor staining which stayed elevated for 14 days post wounding.

The LAP treated wounds also showed a dose dependent decrease in staining for TGF β 3 at the wound site. This decrease in TGF β 3 staining compared to control and sham control wounds was most marked at 24 hours and 4 days post wounding.

All of these effects (noted above) with the exogenous addition of the LAP, i.e. increase in inflammatory cells, particularly monocytes and macrophages, increase in extracellular matrix deposition, e.g. fibronectin and collagen, increase in TGF β receptor staining are identical to effects observed when exogenous TGF β 1 itself is added to the wound.

Furthermore, wound healing was accelerated in a dose dependant fashion in the LAP treated wounds, using a number of parameters (e.g. completion of epithelialisation, maturation of the granulation tissue or early deposition of collagen). Therefore exogenous addition of LAP has the same effect on wound healing as has been reported for exogenous addition of TGF β 1.

These findings are not at all what might be predicted from the prior art which teaches that exogenous LAP neutralises TGF β 1 and hence would be expected to have anti-scarring activity. Instead it acts like exogenous addition of TGF β 1 and increasing the rate of wound healing, but has no anti-scarring activity.

Exogenous addition of LAP therefore has value in stimulating the healing of wounds. LAP is particularly useful for chronic wounds (such as venous ulcers, diabetic ulcers, pressure sores, etc.), as well as acute surgical incisions.

CLAIMS

1. The use of Latency Associated Peptide, or a functional analogue thereof, for the manufacture of a medicament for increasing the rate of wound healing.
2. The use according to claim 1 wherein the Latency Associated Peptide, or functional analogue thereof, is capable of maintaining a Transforming Growth factor β in a latent state.
3. The use according to claim 2 wherein the Latency Associated Peptide, or functional analogue thereof, is capable of maintaining Transforming Growth factor β 1 and / or Transforming Growth factor β 2 in a latent state.
4. The use according to any preceding claim wherein the medicament is for the increasing the rate of healing of acute wounds.
5. The use according to claim 4 wherein the acute wound is one of a penetrative injuries, a burn, nerve damage, resulting from surgery or a wound of an internal organ.
6. The use according to any one of claims 1 to 3 wherein the medicament is for increasing the rate of healing of chronic wounds.
7. The use according to claim 6 wherein the chronic wound is one of diabetic, venous or decubitus ulceration.
8. The use according to any preceding claim wherein the medicament is for increasing the rate of healing of wounds of healing compromised individuals.
9. The use according to claim 8 wherein the healing compromised individual is an elderly human or animal.

10. The use according to any preceding claim wherein the medicament is in the form of a liquid, ointment, cream, gel, hydrogel, powder, aerosol or implant.
11. The use according to any preceding claim for topical application.
12. The use according to any preceding claim wherein the medicament contains from 1ng to 10mg of Latency Associated Peptide or functional analogue thereof.
13. The use according to any preceding claim wherein Latency Associated Peptide or a protein analogue thereof is used and is obtained from Transforming Growth factor β expressing tissues, from Transforming Growth factor β expressing cells grown in culture from cells genetically engineered to express Latency Associated Peptide or a protein analogue thereof or from a transgenic animal genetically engineered to express Latency Associated Peptide or a protein analogue thereof.
14. The use according to any one of claims 1 to 12 wherein a functional analogue of Latency Associated Peptide is used and is a chemical or genetically engineered modification of Latency Associated Peptide or a chemically synthesised compound.
15. A method of increasing the rate of wound healing comprising applying to the site of the wound a therapeutically effective amount of Latency Associated Peptide or functional analogue thereof.
16. A composition for the increasing the rate of wound healing comprising a therapeutically effective amount of Latency Associated Peptide or functional analogue thereof and a pharmaceutically acceptable carrier.
17. The composition according to claim 16 in the form of a liquid, ointment, cream, gel, hydrogel, powder, aerosol or implant.

18. A delivery system for use in a gene therapy technique, said delivery system comprising a DNA molecule encoding for a Latency Associated Peptide, or functional peptide analogue thereof, which modulates wound healing, said DNA molecule being capable of being transcribed to lead to the expression of said Latency Associated Peptide, or functional peptide analogue thereof.

19 The use of a delivery system according to claim 18 for use in the manufacture of a medicament for increasing the rate of wound healing.

20. A method of increasing the rate of wound healing comprising administering to a patient in need of treatment a therapeutically effective amount of a delivery system according to claim 18.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 98/00316

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 38/18
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS, WPI, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9217206 A1 (THE VICTORIA UNIVERSITY OF MANCHESTER), 15 October 1992 (15.10.92) --	1-14, 16-19
A	WO 9409812 A (KIRIN BREWERY COMPANY, LIMITED), 11 May 1994 (11.05.94) --	1-14, 16-19
A	WO 9108291 A (GENENTECH, INC.), 13 June 1991 (13.06.91) -- -----	1-14, 16-19

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family


Date of the actual completion of the international search

8 May 1998

Date of mailing of the international search report

01.07.98

Name and mailing address of the ISA/

 European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 cpo nl,
Fax: (+31-70) 340-3016

Authorized officer

CAROLINA GÓMEZ LAGERLÖF

INTERNATIONAL SEARCH REPORT

I. national application No.

PCT/GB 98/ 00316

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15,20
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 15,20
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/04/98

International application No.
PCT/GB 98/00316

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9217206 A1	15/10/92	AU 661840 B AU 1436892 A CA 2105652 A EP 0585242 A JP 6506205 T US 5662904 A	10/08/95 02/11/92 29/09/92 09/03/94 14/07/94 02/09/97
WO 9409812 A	11/05/94	AU 5587094 A CN 1088616 A	24/05/94 29/06/94
WO 9108291 A	13/06/91	AT 131872 T AU 639047 B AU 6744090 A CA 2068204 A DE 69024369 D,T EP 0502036 A,B ES 2083469 T JP 5503003 T	15/01/96 15/07/93 26/06/91 23/05/91 13/06/96 09/09/92 16/04/96 27/05/93